---
uid: 20260215132000
title: Why Hashimoto Thyroiditis Patients Need High Vitamin D Levels
authors: Dr. Dimitris Tsoukalas (Clinic Post)
year: ~2023
url: https://www.drtsoukalas.com/giati_oi_astheneis_me_thireoeiditida_hasimoto_hreiazetai_na_ehoun_ipsila_epipeda_bitaminis_d-su-686.html
tags: [lit, clinic-tsoukalas, thyroid, autoimmune, vitD, inflammation, metabolomics]
aliases: [Tsoukalas-Hashimoto-VitD, Hashimoto-HighVitD]
status: lit-full
parent-moc: [[55-MOCs/Nutrition/Thyroid]] | [[55-MOCs/Autoimmune]] | [[55-MOCs/Tsoukalas-Metabolomics]]
confidence: high
cited_refs: [Ref1_ChenYang, Ref2_Murdaca, Ref3_Finamor, Ref4_Lemke, Ref5_ZhouCRP, Ref6_Wimalawansa, Ref7_TsoukalasCOVID, Ref8_McAuliffe, Ref9_SarandiMetabProf, Ref10_TsoukalasFattyAcids, Ref11_TsoukalasUrinary]
---

# Why Hashimoto Thyroiditis Patients Need High Vitamin D Levels (Tsoukalas, ~2023)

**Source**: Dr Tsoukalas Clinic (Greek → EN translation/edits). **Edits**: Removed promo/booking fluff; bolded claims; structured science; consolidated reps (e.g., \"low VitD ↑ inflam\" once); added wikilinks placeholders.

## TL;DR (Actionable)
- **80-90% Hashimoto patients VitD deficient** → ↑ autoimmunity/inflammation (CRP/TNF↑, IL-10↓).
- **High-dose protocol**: 5,000 IU/day → 50 ng/mL (3-5 months); overcomes resistance [[Ref4_Lemke]].
- **Causal evidence**: Low VitD ↑ CRP/mortality (294k MR study [[Ref5_ZhouCRP]]); monitor via Metabolomic Analysis® (organic/fatty acids predict risk [[Ref10_TsoukalasFattyAcids]]).
- **Immune shift**: ↓ Pro-inflam cytokines, ↑ anti-inflam; personalize foods/sun/supp.

## Key Mechanisms & Evidence
### Vitamin D & Autoimmunity/Hashimoto
Vitamin D deficiency is observed in **80-90% of Hashimoto patients** [[Ref1_ChenYang],[Ref2_Murdaca]]. Low VitD promotes **autoimmunity** via impaired immune regulation.

**Immune Modulation**:
- ↓ Pro-inflammatory (IL-6, TNF-α) + ↑ anti-inflammatory (IL-10).
- **CRP Link**: Bidirectional MR study (294,970 people) shows low VitD causally ↑ CRP/inflammation [[Ref5_ZhouCRP]].

**Resistance Hypothesis**: High-dose VitD overcomes autoimmunity resistance [[Ref4_Lemke]].

### Clinical Outcomes
- Low VitD ↑ **mortality/infection risk** (e.g., sepsis/COVID).
- High VitD (50+ ng/mL) protective; rapid ↑ serum 25(OH)D boosts immunity [[Ref6_Wimalawansa]].

## Protocols & Recommendations
**High-Dose VitD**:
- **Dose**: 5,000 IU/day for 3-5 months → target 50 ng/mL.
- **Monitor**: Metabolomic Analysis® (Tsoukalas method) for organic/fatty acids [[Ref9_SarandiMetabProf],[Ref10_TsoukalasFattyAcids],[Ref11_TsoukalasUrinary]].
- **Safety**: Watch calcemia/oxalate; personalize.

**Natural Sources** (Table):
| Food/Source | VitD Boost |
|-------------|------------|
| Fatty fish (salmon) | High |
| Eggs | Moderate |
| Sun exposure | Optimal |
| Mushrooms/supps | Fill gaps |

## Metabolomic Analysis® for Hashimoto
Tsoukalas protocol: Predicts autoimmune via:
- **Organic Acids**: VitD/C/magnesium/glutathione/ω-3 status.
- **Fatty Acids**: ω-3/ω-6 ratio → inflammation pred [[Ref10_TsoukalasFattyAcids]].
- **Urinary**: Targeted assay for risk [[Ref11_TsoukalasUrinary]].

**Why Usable**: Ties to [[66-Nutrition/Thyroid]] | [[33-PhD/Biomarkers]] | [[44-Clinic/RON/LEDGER]] (track VitD inputs/CRP outputs).

## Key Quotes
> \"Vitamin D acts as an immune-modulator, reducing pro-inflammatory cytokines.\" (Mechanisms)

## Full Bibliography (Zotero-Ready)
| # | Title | Authors | Journal/Year | DOI/PMID/PMC/URL | Note Link |
|---|-------|---------|--------------|------------------|-----------|
|1| The Implication of Vitamin D and Autoimmunity: a Comprehensive Review | Chen-Yen Yang et al. | Clin Rev Allergy Immunol 2018 | PMC6047889<br>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047889/ | [[22-Literature/Refs/Tsoukalas/Ref1_ChenYang_AutoimmunityRev_20260215]] |
|2| Emerging Role of Vitamin D in Autoimmune Diseases: An Update on Evidence and Therapeutic Implications | Giuseppe Murdaca | Autoimmun Rev 2019 | PMID:31323357<br>https://pubmed.ncbi.nlm.nih.gov/31323357/ | [[22-Literature/Refs/Tsoukalas/Ref2_Murdaca_EmergingRoleVitD_20260215]] |
|3| A pilot study assessing the effect of prolonged administration of high daily doses of vitamin D on the clinical course of vitiligo and psoriasis | Danilo C Finamor et al. | Dermatoendocrinol 2013 | PMC3897595<br>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3897595/ | [[22-Literature/Refs/Tsoukalas/Ref3_Finamor_PilotStudyVitD_20260215]] |
|4| Vitamin D Resistance as a Possible Cause of Autoimmune Diseases: A Hypothesis Confirmed by a Therapeutic High-Dose Vitamin D Protocol | Lemke D. et al. | Front Immunol 2021 | 10.3389/fimmu.2021.655739<br>https://www.frontiersin.org/articles/10.3389/fimmu.2021.655739/full | [[22-Literature/Refs/Tsoukalas/Ref4_Lemke_VitDResistance_20260215]] |
|5| Vitamin D deficiency and C-reactive protein: a bidirectional Mendelian randomization study | Ang Zhou, Elina Hyppönen | Int J Epidemiol 2022 | 10.1093/ije/dyac087<br>https://doi.org/10.1093/ije/dyac087 | [[22-Literature/Refs/Tsoukalas/Ref5_ZhouCRP_VitD_20260215]] |
|6| Rapidly Increasing Serum 25(OH)D Boosts the Immune System, against Infections—Sepsis and COVID-19 | Prof. Sunil J. Wimalawansa | Nutrients 2022 | 10.3390/nu14142997<br>https://doi.org/10.3390/nu14142997 | [[22-Literature/Refs/Tsoukalas/Ref6_Wimalawansa_Serum25OHD_20260215]] |
|7| Micronutrient deficiencies in patients with COVID-19: how metabolomics can contribute to their prevention and replenishment | Dimitris Tsoukalas, Evangelia Sarandi | BMJ Nutr Prev Heal 2020 | bmjnph-2020-000169<br>https://nutrition.bmj.com/content/early/2020/11/03/bmjnph-2020-000169 | [[22-Literature/Refs/Tsoukalas/Ref7_TsoukalasCOVID_Micronutrients_20260215]] |
|8| Dietary micronutrients in the wake of COVID-19: an appraisal of evidence with a focus on high-risk groups and preventative healthcare | McAuliffe S et al. | BMJ Nutr Prev Heal 2020 | bmjnph-2020-000100 | [[22-Literature/Refs/Tsoukalas/Ref8_McAuliffe_DietaryMicronutrients_20260215]] |
|9| Metabolic profiling of organic and fatty acids in chronic and autoimmune diseases | Evangelia Sarandi, Dimitris Tsoukalas et al. | Advances in Clinical Chemistry 2020 | S0065242320300755<br>https://www.sciencedirect.com/science/article/pii/S0065242320300755 | [[22-Literature/Refs/Tsoukalas/Ref9_SarandiMetabProf_20260215]] |
|10| Targeted Metabolomic Analysis of Serum Fatty Acids for the Prediction of Autoimmune Diseases | Dimitris Tsoukalas et al. | Front Mol Biosci 2019 | 10.3389/fmolb.2019.00120<br>https://www.frontiersin.org/articles/10.3389/fmolb.2019.00120/full | [[22-Literature/Refs/Tsoukalas/Ref10_TsoukalasFattyAcids_20260215]] |
|11| Prediction of Autoimmune Diseases by Targeted Metabolomic Assay of Urinary Organic Acids | Dimitris Tsoukalas et al. | Metabolites 2020 | https://www.mdpi.com/2218-1989/10/12/502 | [[22-Literature/Refs/Tsoukalas/Ref11_TsoukalasUrinary_20260215]] |

## All Created Notes (Link Hub)
- **Lit Core**: [[22-Literature/20260215_Tsoukalas_Hashimoto_VitD_Full]]
- **Refs (11)**: [[22-Literature/Refs/Tsoukalas/Ref1_ChenYang_AutoimmunityRev_20260215]] | [[22-Literature/Refs/Tsoukalas/Ref2_Murdaca_EmergingRoleVitD_20260215]] | [[22-Literature/Refs/Tsoukalas/Ref3_Finamor_PilotStudyVitD_20260215]] | [[22-Literature/Refs/Tsoukalas/Ref4_Lemke_VitDResistance_20260215]] | [[22-Literature/Refs/Tsoukalas/Ref5_ZhouCRP_VitD_20260215]] | [[22-Literature/Refs/Tsoukalas/Ref6_Wimalawansa_Serum25OHD_20260215]] | [[22-Literature/Refs/Tsoukalas/Ref7_TsoukalasCOVID_Micronutrients_20260215]] | [[22-Literature/Refs/Tsoukalas/Ref8_McAuliffe_DietaryMicronutrients_20260215]] | [[22-Literature/Refs/Tsoukalas/Ref9_SarandiMetabProf_20260215]] | [[22-Literature/Refs/Tsoukalas/Ref10_TsoukalasFattyAcids_20260215]] | [[22-Literature/Refs/Tsoukalas/Ref11_TsoukalasUrinary_20260215]]

## Atomic Notes Extracted (Strong Claims)
| Note | Path | Key Claim |
|------|------|-----------|
| [[66-Nutrition/Thyroid/20260215_VitD_Deficiency_Hashimoto_Prevalence]] | Thyroid | 80-90% Hashimoto pts VitD def → autoimmunity. |
| [[66-Nutrition/Autoimmune/20260215_VitD_Immune_Modulation_Autoimmune]] | Autoimmune | ↓ Pro-inflam (TNF/IL-6), ↑ IL-10. |
| [[66-Nutrition/Inflammation/20260215_VitD_CRP_Causal_Link]] | Inflammation | Low VitD causally ↑ CRP (294k MR [[Ref5_ZhouCRP_VitD_20260215]]). |
| [[33-PhD/Biomarkers/20260215_VitD_Resistance_Hypothesis]] | PhD/Biomarkers | Resistance hypo; high-dose overcomes [[Ref4_Lemke_VitDResistance_20260215]]. |
| [[44-Clinic/RON/20260215_Protocol_HighDose_VitD_Hashimoto]] | Clinic/RON | 5k IU/day 3-5mo → 50 ng/mL; Metabolomics®. |
| [[33-PhD/Biomarkers/20260215_Metabolomics_Autoimmune_Prediction]] | PhD/Biomarkers | Organic/fatty acids pred risk [[Ref10_TsoukalasFattyAcids_20260215],[Ref11_TsoukalasUrinary_20260215]]. |
| [[66-Nutrition/Vitamins/20260215_VitD_Natural_Sources]] | Vitamins | Fish/eggs/sun table; supp gaps.

**Next**: MOC canvas | RON ledger | Site recon.
